drugset / Trial / NCT00191698

Comparison of Atomoxetine and Placebo in Children and Adolescents With ADHD and ODD

NCT00191698

Phase 3 Completed 226 enrolled Eli Lilly and Company
RandomizedCrossoverQuadruple-blindTreatment

Summary

The purpose of this trial is to test the effectiveness of atomoxetine in treating symptoms of ODD in children with ADHD and ODD.

Timeline

Start
2003-12
Primary completion
2005-06
Completion
2007-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Atomoxetine Other / unclassified 1.2 mg/kg Oral
Subject Atomoxetine Other / unclassified 2.4 mg/kg Oral